Clinical Trial Update: Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing Genexol-PM versus Paclitaxel in anthracycline-pretreated metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Genexol-PM (paclitaxel)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN